Table 3. Summary of Agent Indications
Agent Indication
SERMs
Tamoxifen FDA-approved for the treatment of metastatic breast cancer and adjuvant
treatment of breast cancer and to reduce the risk of invasive breast cancer in
premenopausal or post-menopausal women with ductal carcinoma in situ
(DCIS) and/or women at high risk of developing breast cancer.
Raloxifene FDA-approved for the treatment and prevention of osteoporosis in
postmenopausal women and to reduce the risk of invasive breast cancer in
postmenopausal women with osteoporosis and/or postmenopausal women
at increased risk of breast cancer.
Arzoxifene Not FDA-approved for any indication but has been evaluated for breast
cancer prevention and the treatment of osteoporosis in postmenopausal
women. Development has been discontinued by the manufacturer.
Lasofoxifene Not approved by the FDA for any indication. It is approved in Europe by
the European Medicines Agency under the brand name Fablyn (Ligand
Pharmaceuticals, La Jolla, CA) for the treatment of osteoporosis in
postmenopausal women. Lasofoxifene has also been evaluated for breast
cancer prevention in postmenopausal women with osteoporosis.
Aromatase inhibitors
Exemestane FDA-approved for the adjuvant treatment of ER-positive early breast cancer
in postmenopausal women and for treatment of ER-positive advanced
breast cancer in postmenopausal women whose disease has progressed
aer tamoxifen therapy or in combination with everolimus aer failure of
treatment with letrozole or anastrozole. Exemestane is not approved by the
FDA for breast cancer prevention.
Anastrozole FDA-approved for adjuvant treatment of hormone receptor–positive
early breast cancer in postmenopausal women, for first-line treatment of
postmenopausal women with hormone receptor-positive or hormone
receptor-unknown locally advanced or metastatic breast cancer, and for the
treatment of advanced breast cancer in postmenopausal women with disease
progression aer tamoxifen therapy. Anastrozole is not FDA approved for
breast cancer prevention.
Treatment
